Risankizumab for psoriasis

Affiliations

¹ Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA. Electronic address: abcline@wakehealth.edu.
² Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA; Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA.

Comment

Abigail Cline et al. Lancet. 2018.

. 2018 Aug 25;392(10148):616-617.

doi: 10.1016/S0140-6736(18)31781-1. Epub 2018 Aug 7.

¹ Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA. Electronic address: abcline@wakehealth.edu.
² Center for Dermatology Research, Department of Dermatology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA; Department of Pathology, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA; Department of Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, NC 27157-1071, USA.

No abstract available

Comment on

Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
Gordon KB, Strober B, Lebwohl M, Augustin M, Blauvelt A, Poulin Y, Papp KA, Sofen H, Puig L, Foley P, Ohtsuki M, Flack M, Geng Z, Gu Y, Valdes JM, Thompson EHZ, Bachelez H. Gordon KB, et al. Lancet. 2018 Aug 25;392(10148):650-661. doi: 10.1016/S0140-6736(18)31713-6. Epub 2018 Aug 7. Lancet. 2018. PMID: 30097359 Clinical Trial.